Kenvue Inc. (KVUE) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Kenvue Inc. (KVUE) Consumer Business Overview

Kenvue Inc. is a global consumer health leader, marketing a portfolio of iconic brands across self-care, skin health, and essential health categories. As a subsidiary of Johnson & Johnson, Kenvue leverages established brand recognition and distribution networks to maintain a strong position in the competitive consumer defensive sector.

What Is the Investment Thesis for KVUE?

Kenvue Inc. presents a notable research candidate within the consumer defensive sector, driven by its portfolio of well-established brands and consistent demand for essential health products. With a market capitalization of $34.2B and a P/E ratio of 20.45, Kenvue demonstrates financial stability and profitability. The company's gross margin of 58.4% and profit margin of 10.6% highlight efficient operations and pricing power. A dividend yield of 4.70% offers an attractive income stream for investors. Growth catalysts include expanding into emerging markets and launching innovative products within its core segments. Potential risks include increasing competition from generic brands and fluctuations in raw material costs. Kenvue's beta of 0.57 indicates lower volatility compared to the broader market, making it a potentially stable investment during economic uncertainty.

Based on FMP financials and quantitative analysis

KVUE Key Highlights

Market Cap of $34.2B reflects substantial investor confidence in Kenvue's established market presence and brand portfolio.

• P/E Ratio of 20.45 indicates a reasonable valuation relative to earnings, suggesting potential for future appreciation.
• Gross Margin of 58.4% demonstrates efficient cost management and strong pricing power within the consumer health market.
• Dividend Yield of 4.70% provides an attractive income stream for investors, highlighting Kenvue's commitment to shareholder returns.
• Beta of 0.57 suggests lower volatility compared to the broader market, making Kenvue a potentially stable investment option.

Who Are KVUE's Competitors?

KVUE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are KVUE's Key Strengths?

Strong brand portfolio with high consumer recognition.

• Global distribution network and established retail partnerships.
• Diversified product offerings across multiple consumer health categories.
• Consistent demand for essential health products.

What Are KVUE's Weaknesses?

Dependence on a limited number of key brands.

• Exposure to fluctuations in raw material costs.
• Potential for competition from generic brands.
• Relatively new company, still establishing independent operations from Johnson & Johnson.

What Could Drive KVUE Stock Higher?

KVUE catalyst: Launch of new innovative products in the Skin Health and Beauty segment in Q3 2026, targeting younger demographics.

• Expansion into key emerging markets, particularly in Asia and Latin America, expected to drive revenue growth.
• Continued investment in research and development to create differentiated products and formulations.
• Strategic partnerships with e-commerce platforms to enhance online sales and reach a wider audience.

What Are the Key Risks for KVUE?

Increasing competition from generic brands and private label products.

• Fluctuations in raw material costs, impacting profit margins.
• Changes in consumer preferences and health regulations.
• Supply chain disruptions and potential delays in product delivery.
• Integration challenges following the spin-off from Johnson & Johnson.

What Are the Growth Opportunities for KVUE?

• Growth opportunity 1: Expanding into emerging markets represents a significant growth opportunity for Kenvue. These markets, particularly in Asia and Latin America, are experiencing rapid growth in disposable incomes and increasing demand for consumer health products. By tailoring its product offerings to local preferences and leveraging its established distribution network, Kenvue can capture a larger share of these rapidly expanding markets. The global consumer healthcare market is projected to reach $350 billion by 2028, offering substantial potential for Kenvue's growth.
• Growth opportunity 2: Innovation in product development is crucial for Kenvue to maintain its competitive edge and attract new customers. Investing in research and development to create new formulations, delivery systems, and product categories can drive organic growth. For example, developing innovative skincare products with natural ingredients or creating personalized health solutions based on individual needs can appeal to evolving consumer preferences. The global skincare market is projected to reach $180 billion by 2027, providing a significant opportunity for Kenvue's Skin Health and Beauty segment.
• Growth opportunity 3: Strategic acquisitions can enable Kenvue to expand its product portfolio, enter new market segments, and gain access to innovative technologies. Acquiring smaller companies with complementary products or technologies can accelerate Kenvue's growth and enhance its competitive position. For example, acquiring a company specializing in natural or organic health products can strengthen Kenvue's presence in this rapidly growing segment. The mergers and acquisitions market in the consumer health sector is expected to remain active, offering opportunities for Kenvue to expand its footprint.
• Growth opportunity 4: Enhancing its e-commerce presence is essential for Kenvue to reach a wider audience and capitalize on the growing trend of online shopping. Investing in its online platform, improving the user experience, and offering personalized recommendations can drive online sales. Partnering with e-commerce giants like Amazon and Alibaba can further expand Kenvue's reach and market share.
• Growth opportunity 5: Focusing on sustainability and ethical sourcing can enhance Kenvue's brand image and appeal to environmentally conscious consumers. Implementing sustainable manufacturing practices, using eco-friendly packaging, and sourcing ingredients from ethical suppliers can differentiate Kenvue from its competitors and attract a growing segment of consumers who prioritize sustainability.

What Threats Does KVUE Face?

• Increasing competition from established players and emerging brands.
• Changes in consumer preferences and health regulations.
• Economic downturns and reduced consumer spending.
• Supply chain disruptions and rising input costs.

What Are KVUE's Competitive Advantages?

• Strong brand recognition and reputation for quality and efficacy.
• Extensive global distribution network.
• Diversified product portfolio across multiple consumer health categories.
• Significant investment in research and development.
• Economies of scale in manufacturing and distribution.

What Does KVUE Do?

Kenvue Inc., established in 2022, is a consumer health company operating worldwide. Spun off from Johnson & Johnson, Kenvue inherited a rich legacy of trusted brands and a global distribution network. The company is structured into three primary segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment focuses on over-the-counter medications and solutions for common ailments, featuring brands like Tylenol for pain relief, Nicorette for smoking cessation, and Zyrtec for allergy relief. The Skin Health and Beauty segment offers a range of products for face and body care, hair care, and sun protection, marketed under brands such as Neutrogena, Aveeno, and OGX. The Essential Health segment provides products for oral care, baby care, women's health, and wound care, including Listerine, Johnson's, Band-Aid, and Stayfree. Kenvue's headquarters are located in Skillman, New Jersey, and the company employs approximately 22,000 people. Kenvue leverages its strong brand equity and established retail partnerships to maintain a competitive edge in the consumer health market. The company's focus on innovation and product development aims to address evolving consumer needs and preferences, ensuring sustained growth and market leadership.

What Products and Services Does KVUE Offer?

• Develops and markets over-the-counter medications for pain relief, cold and allergy, and digestive health.
• Offers skincare and beauty products for face, body, and hair care.
• Provides essential health products for oral care, baby care, women's health, and wound care.
• Sells products under well-known brands such as Tylenol, Neutrogena, Listerine, and Band-Aid.
• Operates through three segments: Self Care, Skin Health and Beauty, and Essential Health.
• Distributes products globally through retail channels and online platforms.
• Focuses on innovation and product development to meet evolving consumer needs.

How Does KVUE Make Money?

• Develops and manufactures consumer health products across multiple categories.
• Markets and distributes products through a global network of retailers and online channels.
• Generates revenue through the sale of branded products to consumers.
• Invests in research and development to create new products and improve existing ones.
• Leverages brand equity and marketing to maintain a competitive advantage.

What Industry Does KVUE Operate In?

Kenvue Inc. operates within the global consumer health market, a sector characterized by steady growth and resilience to economic downturns. The industry is driven by increasing consumer awareness of health and wellness, an aging population, and rising disposable incomes in emerging markets. Key trends include a growing demand for natural and organic products, personalized health solutions, and convenient over-the-counter treatments. The competitive landscape includes established players like Kenvue, as well as generic drug manufacturers and emerging direct-to-consumer brands. Kenvue's strong brand portfolio and global distribution network position it favorably to capitalize on these trends and maintain its market share.

Who Are KVUE's Key Customers?

• Individual consumers seeking over-the-counter medications and personal care products.
• Retailers, including pharmacies, supermarkets, and online marketplaces.
• Hospitals and healthcare providers.
• Distributors and wholesalers.

Kenvue Inc. Financial Trajectory

Kenvue Inc. (KVUE) reported $3.96B in revenue for Q2 FY2026, reflecting 1.2% growth compared to the prior quarter. The company recorded net income of $456.0M, with diluted EPS of $0.24. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Consumer Defensive company. Across the four most recent quarters, KVUE averaged $0.22 in diluted EPS.

Company Profile

Kenvue Inc. operates in the Household & Personal Products industry within the Consumer Defensive sector. It is headquartered in Summit, US. The company is led by CEO Kirk L. Perry. KVUE has traded publicly since 2023.

How Kenvue Inc. Is Valued

Kenvue Inc. carries a market capitalization of $34.2B, placing it in the large-cap category. Analyst price targets span from $19.00 to $20.00, with a consensus of $19.50. At the current price of $17.79, that implies approximately 10% upside potential. Relative to its peer group, KVUE's quantitative score of 70/100 is roughly in line with the peer average of 64/100.

Return on equity for Kenvue Inc. stands at 15.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.0%, showing how much profit it generates from its asset base. KVUE trades at a trailing price-to-earnings ratio of 20.45, below the Consumer Defensive sector average of ~27.60x. Its free cash flow yield is 4.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.98 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 4.4%, the inverse of the P/E and a quick read on earnings relative to price.

Kenvue Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.16 places it in the grey zone, a middle ground that warrants monitoring.

Kenvue Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 7.4% above estimates on average.

Over the past six months, Kenvue Inc. insiders filed 22 SEC Form 4 transactions — 5 sales and 17 purchases. On net that is roughly 75K shares acquired (about $871K) — insiders putting money in tends to read as conviction.

KVUE Financials

Next earnings report: Nov 2, 2026

KVUE Latest News

KVUE Analyst Consensus

KVUE MoonshotScore

Latest Kenvue Inc. Analysis

What Investors Ask About Kenvue Inc. (KVUE) — Consumer Defensive

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources